
Release date: 2024-08-06 17:26:14 Article From: Lucius Laos Recommended: 258
Capmatinib is an oral drug manufactured by Novartis Pharmaceutical. It is a tyrosine kinase inhibitor that specifically targets the c-Met receptor. Capmatinib has shown durable efficacy in the treatment of METex14-mutated NSCLC patients.
According to market research, there are several brands of drugs available in the market for patients to choose from.
The price of capmatinib (200mg*60 tablets) produced by Lucius Pharmaceutical in Laos is about 2,650 yuan per box.
Bangladesh Everest Pharmaceutical's product of the same specification (200mg*56 capsules) is sold at a slightly higher price, about 3,600 yuan per box.
The price of capmatinib (200mg*60 tablets) of Novartis's Rahika brand is about 12,500 yuan.
Novartis Pharmaceuticals in Switzerland provides two doses of capmatinib (200mg*60 capsules and 150mg*60 capsules), and the combined price is about 31250 yuan per box.
There are a few things that patients must be aware of when using this drug:
Capmatinib may increase the patient's sensitivity to light, triggering a photosensitization response. During the use of capmatinib, patients should be advised to take precautions and limit direct exposure to intense UV light.
This includes wearing long-sleeved clothing when the sun is strong, wearing a wide-brimmed hat and sunglasses, and using a sunscreen with a high SPF value. Patients should avoid outdoor activities at noon to reduce the risk of photosensitivity.
Capmatinib is embryo-fetal toxic and can cause harm to the fetus. Women of childbearing potential should be informed of potential fetal risks during and for a period of time after capmatinib treatment, as directed by their physician.
To avoid unwanted pregnancies, patients are advised to use effective contraceptive measures such as the use of condoms, intrauterine devices, or oral contraceptives. Patients should also undergo regular gynaecological examinations to ensure the effectiveness of contraception. For male patients, if the female partner has a birth plan, they should also be informed of the potential fetal risks and use appropriate contraception.
[Warm Tips] When purchasing, carefully check the name, specification, approval number, manufacturer, production date, expiration date and other information of the drug to ensure the authenticity and effectiveness of the drug.
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizu···【more】
Recommended:1592025-17-12
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended:3992024-09-07
On December 12, 2025, the U.S. Food and Drug Administration (FDA) approved niraparib in combination ···【more】
Recommended:1532025-15-12
The U.S. Food and Drug Administration (FDA) announced today that it has approved Omisirge (omidubice···【more】
Recommended:1712025-10-12
On December 4, 2025, the U.S. Food and Drug Administration (FDA) approved lisocabtagene maraleucel (···【more】
Recommended:1532025-08-12
On December 3, 2025, the U.S. Food and Drug Administration (FDA) granted full approval to pirtobruti···【more】
Recommended:1872025-04-12
Primary analysis data from the randomized, double-blind, placebo-controlled phase III HER2CLIMB-02 s···【more】
Recommended:1672025-01-12
The Cure SMA Foundation, a global leading non-profit organization dedicated to spinal muscular atrop···【more】
Recommended:1622025-27-11

Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp: